Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[18F]NOTA-ABY030
- Development stage
- Phase 1
- Lead developer
- Vanderbilt-Ingram Cancer Center
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
[18F]NOTA-ABY030 is a radiopharmaceutical diagnostic agent composed of an anti-EGFR affibody molecule (ABY030) conjugated with the chelator NOTA, which is then radiolabeled with Fluorine-18 ([18F]). This agent is designed for Positron Emission Tomography/Computed Tomography (PET/CT) imaging. Its mechanism involves the specific binding of the anti-EGFR affibody component to the epidermal growth factor receptor (EGFR), which is frequently overexpressed in various cancer types. The small size of the affibody molecule contributes to rapid clearance and improved tumor-to-background contrast, enhancing its diagnostic utility. It is currently being evaluated in clinical trials for its safety, tolerability, and diagnostic performance in patients with head and neck squamous cell carcinoma (HNSCC) to identify indeterminate primary and/or metastatic lesions.
- Other names
- 18F-labeled anti-EGFR affibodyFluorine-18 NOTA-ABY-030Fluorine18 NOTA-ABY-030Fluorine 18 NOTA-ABY-030
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on [18F]NOTA-ABY030.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [18F]NOTA-ABY030.